This article evaluates the evidence supporting use of the tenofovir disoproxil fumarate (TDF) plus lamivudine (3 ​TC) combination as a dual nucleoside backbone within a triple drug antiretroviral regimen. Key trials that assess the relative efficacy, safety and resistance profile of 3 ​TC and emtricitabine (FTC) are discussed. Clinical use of 3 ​TC and FTC with two tenofovir prodrugs –TDF and tenofovir alafenamide (TAF) – is presented. Recommendations from various international guidelines for the construction of triple and emerging dual regimens are summarised. In conclusion, data suggest the therapeutic equivalence of 3 ​TC and FTC, especially when 3 ​TC is combined with TDF.

本文评估了支持在三药抗逆转录病毒治疗方案中使用富马酸替诺福韦二吡呋酯 (TDF) 加拉米夫定 (3 TC) 组合作为双核苷主链的证据。讨论了评估 3 TC 和恩曲他滨 (FTC) 相对疗效、安全性和耐药性的关键试验。介绍了 3 TC 和 FTC 与两种替诺福韦前药（TDF 和替诺福韦艾拉酚胺 (TAF)）的临床应用。总结了各种国际指南关于构建三重疗法和新兴双重疗法的建议。总之，数据表明 3 TC 和 FTC 的治疗等效性，特别是当 3 TC 与 TDF 联合使用时。